Alcohol-Related Mortality in Patients With Psoriasis-Reference-Cited by-同舟云学术

Alcohol-Related Mortality in Patients With Psoriasis

Published:2017-12-01 Issue:12 Volume:153 Page:1256
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Parisi Rosa¹,Webb Roger T.²,Carr Matthew J.²,Moriarty Kieran J.³,Kleyn C. Elise⁴,Griffiths Christopher E. M.⁴⁵,Ashcroft Darren M.¹⁵⁶

Affiliation:

1. Centre for Pharmacoepidemiology and Drug Safety, School of Health Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, England

2. Centre for Mental Health and Safety, School of Health Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, England

3. Bolton NHS Foundation Trust, Bolton, England

4. Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, England

5. NIHR Manchester Biomedical Research Centre, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, England

6. NIHR Greater Manchester Patient Safety Translational Research Centre, University of Manchester, Manchester Academic Health Science Centre, Manchester, England

Publisher

American Medical Association (AMA)

Subject

Dermatology

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials;Journal of the American Academy of Dermatology;2024-08

2. Dosis‐Wirkungs‐Beziehung zwischen Alkoholkonsum und Psoriasis: Systematische Übersicht und Metaanalyse;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-05

3. Dose‐response analysis between alcohol consumption and psoriasis: A systematic review and meta‐analysis;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-04-28

4. Risk of developing psychiatric disease among adult patients with skin disease: A 9‐year national register follow‐up study in Norway;Skin Health and Disease;2023-10-20

5. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial;Journal of the American Academy of Dermatology;2023-09